Thomsen–Friedenreich antigen explained

Thomsen–Friedenreich antigen (Galβ1-3GalNAcα1-Ser/Thr) is a disaccharide that serves as a core 1 structure in O-linked glycosylation.^[1] First described by Thomsen as a red blood cell's antigen, later research have determined it to be an oncofetal antigen.^[2] it is present in the body as a part of membrane transport proteins where it is normally masked from the immune system.^[3] It is commonly demasked in cancer cells, with it being expressed in up to 90% of carcinomas, making it a potential target for immunotherapy.

External links

• Dippold . W. . Steinborn . A. . Büschenfelde . K. H. M. z. . The Role of the Thomsen-Friedenreich Antigen As a Tumor-Associated Molecule . Environmental Health Perspectives . 88 . 255–7 . 1990 . 2272320 . 1568008 . 10.2307/3431086. 3431086 .
• King . MJ . Holburn . AM . Radioassays of blood group M, N and T (Thomsen-Friedenreich) antigens . Immunology . 38 . 1 . 129–36 . 1979 . 511213 . 1457886.
• Singh . R. . Campbell . BJ . Yu . LG . Fernig . DG . Milton . JD . Goodlad . RA . Fitzgerald . AJ . Rhodes . JM . Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44 . Glycobiology . 11 . 7 . 587–92 . 2001 . 11447138 . 10.1093/glycob/11.7.587. free .
• Wolf . Michael F. . Koerner . Ulrike . Schumacher . Kurt . Specificity of reagents directed to the Thomsen-Friedenreich antigen and their capacity to bind to the surface of human carcinoma cell lines . Cancer Research . 46 . 4 Pt 1 . 1779–82 . 1986 . 2418954 .
• Uhlenbruck . G. . The Thomsen-Friedenreich (TF) Receptor: An Old History with New Mystery . Immunological Investigations . 10 . 3 . 251–64 . 1981 . 7037612 . 10.3109/08820138109093459.
• 1568008 . 2272320 . 88 . The role of the Thomsen-Friedenreich antigen as a tumor-associated molecule . August 1990 . Environ. Health Perspect. . 255–7 . Dippold . W . Steinborn . A . Meyer . Büschenfelde . KH . 10.2307/3431086. 3431086 .

Notes and References

1. Yu. Lu-Gang. 2007. The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression. Glycoconjugate Journal. 24. 8. 411–20. 10.1007/s10719-007-9034-3. 17457671. 9264538.
2. Kurtenkov. Oleg. 2020-03-24. Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential. BioMed Research International. 2020. 1–12. 10.1155/2020/9747040. 32280709. 7128052. 2314-6133. free.
3. Karsten. U.. Goletz. S.. July 2015. What controls the expression of the core-1 (Thomsen—Friedenreich) glycotope on tumor cells?. Biochemistry (Moscow). en. 80. 7. 801–807. 10.1134/S0006297915070019. 26541995. 17278587. 0006-2979.